Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.
Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.
The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.
Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.
Previous studies have demonstrated tivantinib prolonged progression-free survival and overall survival in hepatocellular carcinoma.
Patients were enrolled regardless of portal vein thrombosis status and were unable to tolerate other curative therapies.
Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.
Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.
Researchers randomly assigned 459 patients to receive SIRT with 90Y-loaded resin microspheres for 2 to 5 weeks or oral sorafenib 400 mg twice daily continuously.
A previous study demonstrated that TACE plus orantinib insignificantly prolonged progression-free survival, though it did not improve OS.
Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.
The 1-year control rate was 99%, the 2-year control rate was 95%, and the median time to progression was 9 months.
The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.
Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.
The Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was highly predictive of hepatocellular carcinoma (HCC) recurrence risk.
Polycystic kidney disease (PKD) may increase one's risk of developing cancer of the liver, colon, and kidney.
The kinase inhibitor regorafenib conferred improved overall survival in patients with unresectable hepatocellular carcinoma (HCC).
For patients with hepatocellular carcinoma, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved survival.
Treatment with sorafenib is not effective in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
People who have three or more alcoholic drinks per day could be raising their odds for liver cancer.
Survival rates are improving for many people with cancers of the breast, prostate, lung, liver, and colon or rectum.
Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.
By analyzing data from international databases, researchers develop an alternative to the Child-Pugh system.
Safety and efficacy of sorafenib, the standard of care for advanced hepatocellular carcinoma, in older patients, evaluated.
Patients with liver cancer whose tumors cells have less differentiated mesenchymal phenotype and CD44 are less likely to respond to sorafenib.
Heavier people might be more prone to liver cancer, insulin problems.
NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs SurvivalOctober 10, 2014
Poorly differentiated pancreatic neuroendocrine carcinoma (PNEC) grade 3 tumors demonstrate lower survival after radical resection of PNETs.
Researchers have discovered that a protein called apoptosis inhibitor of macrophage (AIM) prevents tumor development in liver cells.
Sorafenib Plus Selective Internal Radiation Therapy (SIRT) Improves Survival for Patients with Liver CancerSeptember 10, 2014
Patients with advanced hepatocellular carcinoma may benefit from combined therapy of sorafenib and selective internal radiation therapy.
Researchers found no survival difference found between patients receiving everolimus or placebo.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified